Dose-Ranging Study of A006 DPI, in Adult Asthma Patients
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, active- and placebo-controlled, single-dose, seven-arm, crossover
and dose-ranging design. This study aims to evaluate the efficacy and initial safety
profiles, and to identify the optimum dose of A006, from a select dose-range for future
clinical PK/PD and Phase III studies. This study is to be conducted in generally healthy,
adult subjects who have mild-to-moderate persistent asthma for at least 6 months prior to
Screening.